ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01002703
Recruitment Status : Unknown
Verified October 2009 by University of Leipzig.
Recruitment status was:  Recruiting
First Posted : October 27, 2009
Last Update Posted : August 12, 2011
Sponsor:
Collaborators:
Celgene Corporation
Mundipharma Pte Ltd.
Amgen
Information provided by:
University of Leipzig

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : October 2012
  Estimated Study Completion Date : October 2014